超声引导高强度聚焦超声去血管化子宫肌瘤的可行性研究
本研究旨在建立超声引导高强度聚焦超声(USgHIFU)去血管化子宫肌瘤的可行性。采用超声彩色多普勒血流成像(CDFI)和B型超声靶向肌瘤血管,用高强度聚焦超声点覆盖并消融血管。共治疗42个肌瘤(体积66.98 ± 4.00 cm³),治疗后CDFI显示40个肌瘤无血流检出;6个月无灌注体积率为75.23% ± 34.77%(n = 40)。治疗后1个月和6个月肌瘤体积平均缩小分别为38.20%和43.89%(p < 0.001),子宫肌瘤症状与生活质量评分在治疗后1个月和6个月分别降低9.43%和26.66%(p < 0.001)。未观察到严重不良事件。本研究证明USgHIFU诱导肌瘤去血管化可行,尚需更多研究评估安全性和有效性。
要点
- USgHIFU去血管化后CDFI显示42个肌瘤中40个无血流检出。
- 6个月无灌注体积率为75.23% ± 34.77%(n = 40)。
- 肌瘤体积在1个月和6个月分别平均缩小38.20%和43.89%(p < 0.001)。
核心结论
- 本研究证明USgHIFU诱导子宫肌瘤去血管化可行,尚需更多研究评估安全性和有效性。
研究设计与样本
- 可行性研究,采用超声引导高强度聚焦超声(USgHIFU),以超声彩色多普勒血流成像(CDFI)和B型超声靶向肌瘤血管,治疗42个体积为66.98 ± 4.00 cm³的肌瘤。
关键影像表现/征象
- 治疗后CDFI显示42个肌瘤中40个无血流检出。
- 6个月无灌注体积率为75.23% ± 34.77%(n = 40)。
- 肌瘤体积在治疗后1个月平均缩小38.20%,6个月平均缩小43.89%(p < 0.001)。
- 子宫肌瘤症状与生活质量评分在治疗后1个月降低9.43%,6个月降低26.66%(p < 0.001)。
临床应用与阅片要点
- 作者认为USgHIFU诱导肌瘤去血管化可行,但尚需更多研究评估安全性和有效性。
局限性
- 作者指出尚需更多研究评估安全性和有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
This study aimed to establish the feasibility of ultrasound-guided high-intensity focused ultrasound (USgHIFU) for devascularization of uterine fibroids. Ultrasound color Doppler flow imaging (CDFI) and B-mode imaging were used to target fibroid vascularity. The vessels were covered and ablated by high-intensity focused ultrasound spots. In this study, 42 fibroids with a volume of 66.98 ± 4.00 cm3 were treated. No blood flow was detected by post-treatment CDFI in 40 fibroids. The 6-mo non-perfusion volume rate was 75.23% ± 34.77% (n = 40). The mean shrinkage in fibroid volume was 38.20% and 43.89%, respectively, at 1 and 6 mo after treatment (p < 0.001). The uterine fibroid symptom and quality of life scores were reduced by 9.43% at 1 mo and 26.66% at 6-mo after treatment (p < 0.001). No serious adverse event was observed. This study demonstrates the feasibility of USgHIFU-induced fibroid devascularization, and more studies are required for the evaluation of safety and efficacy.
引用
- Zhou Y, Ji X, Niu J, et al. Ultrasound-Guided High-Intensity Focused Ultrasound for Devascularization of Uterine Fibroid: A Feasibility Study. Ultrasound Med Biol. 2021. PMID: 34147312. doi:10.1016/j.ultrasmedbio.2021.05.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。